HC Wainwright Estimates Surrozen FY2024 Earnings

Surrozen, Inc. (NASDAQ:SRZN) – Stock analysts at HC Wainwright issued their FY2024 earnings per share estimates for Surrozen in a research note issued on Thursday, January 30th. HC Wainwright analyst M. Caufield expects that the company will post earnings of ($8.49) per share for the year. HC Wainwright currently has a “Buy” rating and a $32.00 target price on the stock. The consensus estimate for Surrozen’s current full-year earnings is ($8.49) per share. HC Wainwright also issued estimates for Surrozen’s Q4 2024 earnings at ($2.54) EPS, Q1 2025 earnings at ($2.71) EPS, Q2 2025 earnings at ($2.69) EPS, Q3 2025 earnings at ($2.67) EPS, Q4 2025 earnings at ($2.64) EPS, FY2025 earnings at ($10.71) EPS, FY2026 earnings at ($11.68) EPS, FY2027 earnings at ($13.81) EPS, FY2028 earnings at ($15.84) EPS and FY2029 earnings at ($16.24) EPS.

Surrozen (NASDAQ:SRZN) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($2.77) by $2.33. The company had revenue of $10.00 million for the quarter.

Separately, Guggenheim raised Surrozen from a “neutral” rating to a “buy” rating and set a $45.00 target price for the company in a report on Friday, January 3rd.

Surrozen Price Performance

NASDAQ SRZN opened at $11.31 on Monday. The stock’s fifty day moving average price is $11.65 and its 200 day moving average price is $10.17. Surrozen has a 1 year low of $6.00 and a 1 year high of $18.17.

Hedge Funds Weigh In On Surrozen

An institutional investor recently raised its position in Surrozen stock. Stonepine Capital Management LLC raised its holdings in Surrozen, Inc. (NASDAQ:SRZN) by 66.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 110,000 shares of the company’s stock after acquiring an additional 43,916 shares during the period. Surrozen makes up approximately 0.8% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 24th largest position. Stonepine Capital Management LLC owned about 3.43% of Surrozen worth $1,318,000 as of its most recent SEC filing. Institutional investors and hedge funds own 66.57% of the company’s stock.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.